REP 2139
Alternative Names: REP 2139; REP 2139 calcium chelate; REP 2139 magnesium chelate; REP 2139-Ca; REP 2139-Mg; REP 9AC'Latest Information Update: 12 Aug 2024
At a glance
- Originator REPLICor
- Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
- Mechanism of Action Hepatitis B virus replication inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Hepatitis B; Hepatitis D
Most Recent Events
- 05 Jun 2024 Efficacy data from the REPLICor Compassionate Access Program in Hepatitis B and Hepatitis D presented at European Association for the Study of the Liver Congress 2024 (EASL-2024)
- 18 May 2024 Updated efficacy and safety data from a compassionate use programme in Hepatitis B and Hepatitis D presented at the Digestive Disease Week 2024 (DDW-2024)
- 10 Nov 2023 Efficacy and adverse events data from compassionate access trial in Hepatitis B and Hepatitis D presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)